News | February 28, 2026
Novartis completes $12 billion acquisition of Avidity Biosciences
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Subscribe To Our Newsletter & Stay Updated
